首页 > 市场调查报告书 > 医疗设备

医学影像诊断手术用器具电子医疗设备核子医学

市场调查报告书

商品编码

1419134

影像导引放射治疗市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按类型、应用、成像类型、最终用户和地理位置

Image Guided Radiotherapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Application, Imaging Type, End Users, and Geography

出版日期: 2023年11月12日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

根据我们关于「2030 年影像导引放射治疗市场预测 - 全球分析 - 按类型、应用、成像类型和最终用户」的最新研究报告，2022 年市场估值为 18.14 亿美元，预计将达到2030年将达到56.5亿；预计2022-2030年CAGR为15.3%。

该市场的成长归因于全球癌症盛行率的上升以及技术先进系统的引入。此外，癌症筛检计划和标准指南的实施预计将为市场成长提供成长机会。然而，影像导引放射治疗的高成本将阻碍市场成长。

全球卫生系统的癌症盛行率正在大幅增加。根据世界卫生组织 (WHO) 的数据，2019 年全球约有 960 万人死于癌症。根据同一来源，大肠直肠癌、肝癌、前列腺癌、肺癌和胃癌在男性中最常见，而乳癌、大肠癌和子宫颈癌在女性中最常见。

据英国癌症研究中心称，2020年，英国每年约有16万人死于癌症。据世界卫生组织称，癌症是全球死亡的主要原因之一，到 2020 年将导致约 1,000 万人死亡。 2020 年最常见的癌症是乳癌（226 万例）和肺癌（221 万例）。根据美国癌症协会预测，到 2040 年，全球癌症负担预计将达到约 2,840 万例，较 2020 年增加 47%，其中由于人口变化，发展中国家的增加幅度更大。然而，全球化和经济成长可能加剧风险因素的增加，从而进一步加剧这种情况。全球癌症观察站（GLOBOCAN）估计，2020年全球有1930万癌症病例。GLOBOCAN预测，2040年印度癌症病例将比2020年上升至208万，成长57.5%。据世界卫生组织称，全球有近230 万名女性被检测出患有乳腺癌，2020 年约有685,000 人因此死亡。据Advocate Health Care 称，超过60% 的癌症患者接受某种形式的放射治疗，作为其治疗的一部分。治疗。这是因为放射疗法在对抗多种类型的癌症方面非常有效，因为它会破坏癌细胞的繁殖能力。影像导引放射治疗使放射治疗师能够更好地定位目标区域，并在治疗前甚至治疗期间将放射束引导至肿瘤。因此，癌症的高盛行率预计将推动影像导引放射治疗的采用。

根据世界卫生组织 2021 年 3 月发布的资料，超过 50% 的癌症患者将放射治疗作为癌症管理和护理的一部分。此外，根据相同的资料，放射疗法主要用于治疗最常见的癌症类型，例如大肠癌、肺癌、乳癌和子宫颈癌。从患者的角度来看，早期发现和诊断可以避免不必要的痛苦和痛苦。它还可以减少治疗规模和成本。此外，政府意识将推动市场。例如，英国公共卫生部与英国卫生部和英国国民医疗服务体系 (NHS England) 合作，领导了「明确癌症」计画。该计划旨在透过提高公众对癌症迹象和症状的认识来改善癌症的早期诊断，并进一步敦促人们立即去看医生。

技术先进系统的引入推动了影像导引放射治疗市场的成长

成像是诊断过程的基本部分。从超音波到 MRI 和 CT 扫描，放射科医生利用医学影像来正确诊断和治疗疾病。此外，医生还使用影像技术来确定特定疗法是否有效治疗了患者。在过去的几十年里，成像能力急剧增强。成像技术取得了许多进步。这项进展对于提供准确的诊断和改善患者护理非常重要。这些进步以及人工智慧和数位技术的力量提高了提供和完成患者护理的程序效率。人工智慧（AI）有助于改善医疗保健产业的各个方面，医学影像技术是受益最大的领域之一。人工智慧正在应用于先进的成像设备，可以帮助更早发现疾病，并在诊断和早期治疗过程中进行指导。

2021年8月，印度第二大多专科医院Manipal Hospitals推出了先进的Radixact系统，配备Synchrony Automatic即时运动同步技术，用于精确治疗癌症患者。飞利浦于 2023 年透过 Zenition 10 扩展了公司的行动 C 臂产品组合。2023 年，GE Healthcare 透过 AIR 技术扩展了 PET/MR 功能，以提高诊断精度、治疗评估和患者舒适度。 2023 年，Pixxoscan 的推出扩大了 GE Healthcare 的 MRI 造影剂产品组合。 2022 年 2 月，印度 Saket Max 癌症护理研究所 (MICC) 的放射肿瘤科推出了 Radixact X9 Tomotherapy，结合第二代同步呼吸运动管理系统。这种针对癌症患者的放射治疗采用基于人工智慧（AI）的即时追踪和治疗实施方式，确保放射治疗过程中不会因胸部或腹部呼吸运动而错过肿瘤。 2021年9月，SkinCure Oncology宣布了积极的临床试验结果，展示了影像导引表浅放射治疗（IGSRT）治疗基底细胞癌（BCC）和鳞状细胞癌（SCC）的积极资料（治癒率99.3%）。因此，此类技术进步预计将推动影像导引放射治疗市场的成长。

基于类型的见解

影像导引放射治疗市场依类型分为产品和服务。产品领域在 2022 年占据最大的市场份额。服务领域预计在 2022 年至 2030 年期间CAGR最高，达到 15.5%。人们对放射治疗的认识不断提高，从而增加了对直线加速器 (LINAC) 和 MRI-LINAC 等放射治疗设备的需求，这些设备有助于为大量患者提供治疗。此外，肿瘤中心的巨大成长，进一步产生了对放射治疗设备的需求，推动了产品领域并促进了影像导引放射治疗市场的成长。

基于应用程式的见解

根据应用，影像导引放射治疗市场分为乳癌、肺癌、胃肠癌、摄护腺癌、妇科癌症、头颈癌等。乳癌细分市场在 2022 年占据最大的市场份额。预计肺癌细分市场在 2022 年至 2030 年期间CAGR最高，达到 16.3%。

基于成像类型的见解

根据影像学类型，影像导引放射治疗市场分为磁振造影（MRI）、正子断层扫描（PET）、电脑断层扫描（CT）影像等。磁振造影 (MRI) 领域在 2022 年占据最大的市场份额。电脑断层扫描 (CT) 成像领域预计 2022 年至 2030 年CAGR最高，达到 15.8%。

基于最终用户的见解

根据最终用户，影像导引放射治疗市场分为医院、肿瘤中心和放射治疗中心。医院细分市场在 2022 年占据最大的市场份额。肿瘤中心细分市场预计在 2022 年至 2030 年期间的CAGR最高，为 16.0%。

领先企业正在实施扩大市场份额和多元化、推出新产品以及获取新客户群等策略，以挖掘现有的商机。

2023 年 5 月，飞利浦透过 Zenition 10 扩展了其行动 C 臂产品组合。

2023 年 4 月，GE HealthCare 推出 Pixxoscan，扩大了其磁振造影 (MRI) 造影剂产品组合。它为客户提供了两种领先的大环分子：Clariscan（钆特酸）和 Pixxoscan（钆布醇）。

2023 年 6 月，GE HealthCare 宣布计划利用 AIR 技术扩展其 PET/MR 功能，以提高诊断精度并简化治疗评估，同时提高患者舒适度。

2022年9月，中国监管机构国家药品监督管理局（NMPA）批准了ViewRay的MRIdian磁振造影导引放射治疗系统的销售和使用。

2022年3月，全南大学和顺医院引进「Halcyon 3.0」放射治疗系统并用于综合治疗。 Halcyon 3.0 是一种最先进的放射癌症治疗设备，可提供基于即时影像导引的强度调节放射治疗。

美国食品药物管理局、疾病管制与预防中心 (CDC) 和全球疾病负担研究是准备影像导引放射治疗市场报告时参考的主要和次要来源。

欧洲
- 德国
- 法国
- 义大利
- 西班牙
- 英国
- 欧洲其他地区
亚太
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 12 章：产业格局

併购
协议、合作、合资企业
新产品发布
扩张和其他策略发展

第13章：竞争格局

关键参与者的热图分析
公司定位与专注

第 14 章：影像导引放射治疗市场 - 主要公司概况

ViewRay

注意 - 将为以下公司列表提供类似信息

通用电气医疗集团
日立製作所
西门子公司
皇家飞利浦公司
东芝公司
瓦里安医疗系统公司
视觉RT有限公司
医科达公司
安科瑞公司
堀场集团

第 15 章：附录

词彙表
关于 Insight Partners
市场情报云

简介目录

Product Code: TIPRE00009118

According to our new research study on "Image Guided Radiotherapy Market Forecast to 2030 - Global Analysis - by Type, Application, Imaging Type, and End User," the market was valued at US$ 1.814 billion in 2022 and is projected to reach US$ 5.650 billion by 2030; it is estimated to register a CAGR of 15.3% during 2022-2030.

The market's growth is due to the rising prevalence of cancer worldwide and the introduction of technologically advanced systems. Further, cancer screening programs and the implementation of standard guidelines are expected to provide growth opportunities for the market growth. However, the high cost of image-guided radiotherapy treatment will hinder market growth.

Health systems across the globe are witnessing a substantial increase in the prevalence of cancer. According to the World Health Organization (WHO), in 2019, ~9.6 million deaths were due to cancer across the globe. According to the same source, colorectal, liver, prostate, lung, and stomach cancer are most observed in men, while breast, colorectal, and cervical cancer are the most common among women.

According to Cancer Research UK, in 2020, ~0.16 million people in the UK die each year due to cancer. Cancer is one of the leading reasons of death globally, causing ~10 million deaths in 2020, according to the WHO. The most common forms of cancer in 2020 were breast cancer (2.26 million cases) and lung cancer (2.21 million cases). According to the American Cancer Society, the burden of cancer worldwide is expected to reach ~28.4 million cases by 2040, increased by 47% from 2020, with greater increases in developing countries due to demographic changes. However, this is further compounded by increasing risk factors that can be exacerbated by globalization and a growing economy. The Global Cancer Observatory (GLOBOCAN) estimates that there were 19.3 million cases of cancer worldwide in 2020. GLOBOCAN predicted that cancer cases in India would rise to 2.08 million in 2040 compared to 2020, an increase of 57.5%. According to WHO, nearly 2.3 million women worldwide were detected with breast cancer, and ~685,000 deaths were registered due to the same in 2020. According to Advocate Health Care, over 60% of cancer patients undergo some form of radiation therapy as part of their treatment. This is because radiation therapy is very effective in fighting several types of cancer as it destroys the cancer cell's ability to reproduce. Image-guided radiotherapy allows the radiation therapist to locate the target area better and direct the beam of radiation at the tumor immediately before or even during treatment. Thus, the high prevalence of cancer is anticipated to drive the adoption of image-guided radiotherapy.

According to data published by the WHO in March 2021, over 50% of cancer patients involve radiotherapy as part of cancer management and care. Moreover, according to the same data, radiotherapy is prominently used to treat the most common types of cancer, such as colorectal, lung, breast, and cervical cancer. From the patient's point of view, early detection and diagnosis can prevent unnecessary pain and suffering. It can also reduce the scale and cost of treatment. Further, government awareness will propel the market. For instance, Public Health England, in partnership with the Department of Health and NHS England, leads the "Be Clear on Cancer" program. The program aims to improve early diagnosis of cancer by increasing public awareness of the signs and symptoms of cancer and further urging people to see their doctors without delay.

Introduction of Technologically Advanced Systems Fuels Image-Guided Radiotherapy Market Growth

Imaging is a fundamental part of the diagnostic process. From ultrasounds to MRIs and CT scans, radiologists use medical imaging to diagnose and treat diseases properly. Also, doctors use imaging technologies to determine whether a particular therapy has effectively treated a patient. Over the past couple of decades, the capabilities of imaging have radically increased. Numerous advancements in imaging technologies have occurred. This progress is important in providing accurate diagnoses and bettering patient care. These advancements and the power of AI and digital technology raise better procedural efficiency in providing and accomplishing patient care. Artificial intelligence (AI) helps improve various parts of the healthcare industry, medical imaging technology being one of the fields benefiting greatly. AI is being used in advanced imaging devices, which can help detect diseases earlier and guide them during diagnosis and early treatment.

In August 2021, Manipal Hospitals, India's second largest multi-specialty hospital, launched an advanced Radixact system equipped with Synchrony Automatic, real-time motion synchronization technology for precisely treating cancer patients. Philips expanded the company's mobile C-arm portfolio through Zenition 10 in 2023. In 2023, GE Healthcare expanded PET/MR capabilities with AIR technologies to improve diagnostic precision, treatment evaluation, and patient comfort. In 2023, the launch of Pixxoscan expanded GE Healthcare's MRI contrast agent portfolio. In February 2022, the Department of Radiation Oncology at Max Institute of Cancer Care (MICC), Saket, India, launched Radixact X9 Tomotherapy, combined with the 2nd Generation Synchronized Respiratory Motion Management System. This radiation therapy treatment for cancer patients uses artificial intelligence (AI)-based real-time tracking and treatment delivery to ensure that the tumor is not missed due to chest or abdominal breathing movement during radiation treatment. In September 2021, SkinCure Oncology announced positive clinical trial results, demonstrating positive data (99.3% cure rate) for image-guided superficial radiotherapy (IGSRT) in the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Therefore, such technological advancements are expected to drive the growth of the image-guided radiotherapy market.

Type-Based Insights

The image-guided radiotherapy market is segmented into product and services based on type. The product segment held the largest market share in 2022. The services segment is anticipated to register the highest CAGR of 15.5% during 2022-2030. Increasing awareness about radiation therapy has increased the demand for radiotherapy equipment such as linear accelerators (LINAC) and MRI-LINAC, which help deliver the therapy to large patient populations. Moreover, there has been tremendous growth in oncology centers, further generating the demand for radiotherapy equipment, driving the product segment and contributing to the image-guided radiotherapy market growth.

Application-Based Insights

Based on application, the image-guided radiotherapy market is segmented into breast cancer, lung cancer, gastrointestinal cancer, prostate cancer, gynecological cancers, head and neck cancer, and others. The breast cancer segment held the largest market share in 2022. The lung cancer segment is anticipated to register the highest CAGR of 16.3% during 2022-2030.

Imaging Type -Based Insights

Based on imaging type, the image-guided radiotherapy market is segmented into magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT) imaging, and others. The magnetic resonance imaging (MRI) segment held the largest market share in 2022. The computed tomography (CT) imaging segment is anticipated to register the highest CAGR of 15.8% from 2022 to 2030.

End User-Based Insights

Based on the end user, the image-guided radiotherapy market is segmented into hospitals, oncology centers, and radiotherapy centers. The hospitals segment held the largest market share in 2022. The oncology centers segment is anticipated to register the highest CAGR of 16.0% during 2022-2030.

Leading players are implementing strategies such as expanding and diversifying their market presence, launching new products, and acquiring a new customer base to tap prevailing business opportunities.

In May 2023, Philips expanded its mobile C-arm portfolio with Zenition 10.

In April 2023, GE HealthCare expanded its portfolio of magnetic resonance imaging (MRI) contrast agents with the launch of Pixxoscan. It provides customers access to two leading macrocyclic molecules: Clariscan (gadoteric acid) and Pixxoscan (gadobutrol).

In June 2023, GE HealthCare announced its plans to expand its PET/MR capabilities with AIR technologies to improve diagnostic precision and simplify treatment evaluation while increasing patient comfort.

In September 2022, the National Medical Products Administration (NMPA), China's regulatory authority, approved the sale and use of ViewRay's MRIdian MRI-guided radiation therapy system.

In March 2022, Hwasun Hospital of Chonnam National University introduced the "Halcyon 3.0" radiotherapy system and used it for comprehensive treatment. Halcyon 3.0 is a state-of-the-art radiation cancer treatment device that can deliver intensity-modulated radiation therapy based on real-time image guidance.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are the primary and secondary sources referred to while preparing the image-guided radiotherapy market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Image Guided Radiotherapy Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Image Guided Radiotherapy Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Image Guided Radiotherapy Market - Global Market Analysis

6.1 Image Guided Radiotherapy - Global Market Overview
6.2 Image Guided Radiotherapy - Global Market and Forecast to 2030

7. Image Guided Radiotherapy Market - Revenue Analysis (USD Million) - By Type, 2020-2030

7.1 Overview
7.2 Product
7.3 Services

8. Image Guided Radiotherapy Market - Revenue Analysis (USD Million) - By Application, 2020-2030

8.1 Overview
8.2 Breast Cancer
8.3 Lung Cancer
8.4 Prostate Cancer
8.5 Gastrointestinal Cancer
8.6 Gynecological Cancer
8.7 Head and Neck Cancer
8.8 Others

9. Image Guided Radiotherapy Market - Revenue Analysis (USD Million) - By Imaging Type, 2020-2030

9.1 Overview
9.2 Computed Tomography (CT)
9.3 Magnetic Resonance Imaging (MRI)
9.4 Positron Emission Tomography (PET)
9.5 Others

10. Image Guided Radiotherapy Market - Revenue Analysis (USD Million) - By End User, 2020-2030

10.1 Overview
10.2 Hospitals
10.3 Oncology Centers
10.4 Radiotherapy Centers

11. Image Guided Radiotherapy Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

11.1 North America
- 11.1.1 North America Image Guided Radiotherapy Market Overview
- 11.1.2 North America Image Guided Radiotherapy Market Revenue and Forecasts to 2030
- 11.1.3 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By Type
- 11.1.4 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By Application
- 11.1.5 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By Imaging Type
- 11.1.6 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By End User
- 11.1.7 North America Image Guided Radiotherapy Market Revenue and Forecasts and Analysis - By Countries
  - 11.1.7.1 United States Image Guided Radiotherapy Market
    - 11.1.7.1.1 United States Image Guided Radiotherapy Market, by Type
    - 11.1.7.1.2 United States Image Guided Radiotherapy Market, by Application
    - 11.1.7.1.3 United States Image Guided Radiotherapy Market, by Imaging Type
    - 11.1.7.1.4 United States Image Guided Radiotherapy Market, by End User
  - 11.1.7.2 Canada Image Guided Radiotherapy Market
    - 11.1.7.2.1 Canada Image Guided Radiotherapy Market, by Type
    - 11.1.7.2.2 Canada Image Guided Radiotherapy Market, by Application
    - 11.1.7.2.3 Canada Image Guided Radiotherapy Market, by Imaging Type
    - 11.1.7.2.4 Canada Image Guided Radiotherapy Market, by End User
  - 11.1.7.3 Mexico Image Guided Radiotherapy Market
    - 11.1.7.3.1 Mexico Image Guided Radiotherapy Market, by Type
    - 11.1.7.3.2 Mexico Image Guided Radiotherapy Market, by Application
    - 11.1.7.3.3 Mexico Image Guided Radiotherapy Market, by Imaging Type
    - 11.1.7.3.4 Mexico Image Guided Radiotherapy Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

11.2 Europe
- 11.2.1 Germany
- 11.2.2 France
- 11.2.3 Italy
- 11.2.4 Spain
- 11.2.5 United Kingdom
- 11.2.6 Rest of Europe
11.3 Asia-Pacific
- 11.3.1 Australia
- 11.3.2 China
- 11.3.3 India
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
- 11.4.1 South Africa
- 11.4.2 Saudi Arabia
- 11.4.3 U.A.E
- 11.4.4 Rest of Middle East and Africa
11.5 South and Central America
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Rest of South and Central America

12. Industry Landscape

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration

14. Image Guided Radiotherapy Market - Key Company Profiles

14.1 ViewRay
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies